Everpar Advisors LLC Makes New Investment in Exact Sciences Co. (NASDAQ:EXAS)

Everpar Advisors LLC acquired a new position in Exact Sciences Co. (NASDAQ:EXAS) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,397 shares of the medical research company’s stock, valued at approximately $251,000.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Artisan Partners Limited Partnership lifted its position in shares of Exact Sciences by 11.8% during the 3rd quarter. Artisan Partners Limited Partnership now owns 3,961,514 shares of the medical research company’s stock valued at $270,254,000 after buying an additional 418,770 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Exact Sciences by 11.5% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,858,380 shares of the medical research company’s stock valued at $137,483,000 after buying an additional 192,372 shares during the last quarter. Jennison Associates LLC lifted its position in shares of Exact Sciences by 94.0% during the 4th quarter. Jennison Associates LLC now owns 1,360,917 shares of the medical research company’s stock valued at $100,681,000 after buying an additional 659,235 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Exact Sciences by 2.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,167,909 shares of the medical research company’s stock valued at $86,402,000 after buying an additional 30,831 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Exact Sciences by 5.4% during the 3rd quarter. Northern Trust Corp now owns 1,128,376 shares of the medical research company’s stock valued at $76,978,000 after buying an additional 57,423 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Insider Activity at Exact Sciences

In other Exact Sciences news, insider Jacob A. Orville sold 966 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $61.43, for a total value of $59,341.38. Following the completion of the transaction, the insider now directly owns 7,488 shares in the company, valued at $459,987.84. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Jacob A. Orville sold 966 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $59,341.38. Following the transaction, the insider now directly owns 7,488 shares in the company, valued at $459,987.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jeffrey Thomas Elliott sold 1,888 shares of the stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $61.43, for a total value of $115,979.84. Following the sale, the chief financial officer now owns 2,084 shares of the company’s stock, valued at approximately $128,020.12. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 70,611 shares of company stock worth $4,255,377. 1.30% of the stock is owned by company insiders.

Analyst Ratings Changes

EXAS has been the topic of a number of recent research reports. TheStreet cut Exact Sciences from a “c-” rating to a “d+” rating in a research report on Monday, February 26th. Canaccord Genuity Group dropped their target price on Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. William Blair restated an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 22nd. Finally, Citigroup reiterated a “buy” rating and issued a $100.00 price objective on shares of Exact Sciences in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.07.

Exact Sciences Stock Performance

Shares of EXAS stock opened at $59.48 on Thursday. The company has a 50 day moving average price of $63.64 and a 200-day moving average price of $64.66. Exact Sciences Co. has a 52 week low of $56.05 and a 52 week high of $100.77. The firm has a market capitalization of $10.94 billion, a PE ratio of -52.18 and a beta of 1.26. The company has a quick ratio of 2.07, a current ratio of 2.32 and a debt-to-equity ratio of 0.74.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.26. The firm had revenue of $646.89 million during the quarter, compared to analyst estimates of $638.83 million. Exact Sciences had a negative net margin of 8.17% and a negative return on equity of 6.60%. The business’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.72) earnings per share. As a group, equities research analysts expect that Exact Sciences Co. will post -0.86 earnings per share for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.